background
rapid
antigen
detect
test
radt
increasingli
use
detect
influenza
virus
respiratori
syncyti
viru
rsv
howev
sensit
specif
matter
debat
challeng
clinic
use
object
compar
diagnost
perform
binaxnow
influenza
ab
bni
binaxnow
rsv
bnr
realtim
revers
transcriptas
pcr
rtpcr
viru
isol
direct
immunofluoresc
dif
paediatr
patient
studi
design
novemb
septemb
nasal
wash
symptomat
children
age
year
attend
tertiari
care
centr
test
combin
respect
assay
use
rtpcr
gold
standard
result
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
bni
confid
interv
ci
respect
eleven
falseneg
sampl
rtpcr
ctvalu
higher
rtpcr
posit
test
result
vs
p
twenti
falseposit
sampl
none
cultur
posit
two
test
posit
dif
sensit
specif
ppv
npv
bnr
falseneg
sampl
median
ctvalu
higher
rtpcr
posit
sampl
vs
p
five
falseposit
sampl
detect
three
test
posit
rsv
viru
isol
dif
conclus
radt
high
specif
bnr
superior
bni
howev
rel
low
sensit
limit
use
clinic
decis
make
tertiari
care
paediatr
hospit
influenza
virus
respiratori
syncyti
virus
rsv
caus
acut
respiratori
tract
infect
arti
children
lead
caus
hospit
identif
virus
import
diseas
manag
presenc
infect
may
requir
specif
treatment
ie
oseltamivir
hospit
contain
measur
current
gold
standard
detect
virus
realtim
revers
transcriptas
pcr
rtpcr
howev
perform
hospit
requir
molecular
diagnost
laboratori
special
personnel
equip
instead
rapid
antigen
detect
test
radt
use
assay
easier
cheaper
perform
less
timeconsum
perform
test
depend
factor
like
time
diseas
onset
sampl
qualiti
type
specimen
epidemiolog
paramet
diagnost
valu
clinic
use
radt
influenza
diagnosi
vari
greatli
prompt
us
evalu
diagnost
perform
routin
use
radt
manufactur
aler
binaxnow
two
virus
use
tertiari
care
paediatr
hospit
compar
diagnost
perform
two
radt
binaxnow
influenza
ab
bni
binaxnow
rsv
bnr
rtpcr
sampl
paediatr
patient
attend
tertiari
care
centr
arti
period
almost
eight
consecut
year
discrep
data
subsequ
compar
viru
isol
direct
immunofluoresc
dif
assay
studi
conduct
novemb
septemb
identifi
paediatr
patient
year
attend
erasmu
mcsophia
emerg
depart
outpatientclin
hospit
period
analys
perform
bni
bnr
compar
rtpcr
select
nasal
wash
patient
median
age
month
minimum
month
lower
interquartil
rang
interquartil
rang
male
nasal
wash
obtain
routin
clinic
practic
symptomat
children
test
immedi
sampl
train
laboratori
personnel
use
four
diagnost
method
multipl
sampl
patient
includ
analysi
therefor
patient
refer
case
data
regard
gender
age
hospit
admiss
obtain
electron
patient
file
data
collect
analys
conduct
anonym
sampl
requir
medic
ethic
review
consent
medic
ethic
board
nasal
wash
test
presenc
select
virus
mean
rtpcr
primer
probe
set
use
routin
set
depart
short
rna
dna
extract
use
magnapurelc
roch
diagnost
almer
netherland
total
nucleic
acid
isol
kit
extract
intern
control
addit
known
concentr
phocin
distemp
viru
pdv
phocin
herp
viru
phv
uniplex
rtpcr
use
detect
rsva
rsvb
human
rhinoviru
hrv
parainfluenza
viru
piv
type
adenoviru
adv
human
bocaviru
hbov
duplex
reaction
perform
combin
influenza
viru
pdv
influenza
b
viru
human
coronaviru
hcov
human
metapneumoviru
hmpv
cycl
threshold
valu
ctvalu
defin
posit
viru
rtpcr
develop
inhous
influenza
virus
rsva
valid
rsvb
primer
probe
use
report
dewhurstmaridor
et
al
aler
binaxnow
influenza
b
bni
aler
binaxnow
rsv
bnr
scarborough
main
usa
commerci
avail
vitro
immunochromatograph
assay
qualit
detect
monoclon
antibodi
direct
influenza
b
viru
nucleoprotein
rsv
fusion
protein
antigen
respect
nasal
wash
obtain
use
standard
protocol
rapid
antigen
test
perform
describ
manufactur
analys
test
result
bni
influenza
influenza
b
combin
singl
influenza
bni
dataset
influenza
b
encount
frequent
four
influenza
b
bni
posit
sampl
two
influenza
b
rtpcr
posit
viru
isol
assay
alway
perform
combin
dif
madindarbi
canin
kidney
mdck
cell
line
atcc
tm
human
cell
line
atcc
tm
use
isol
influenza
virus
rsv
respect
viru
cultur
regularli
check
cytopath
effect
light
microscopi
immunofluoresc
fluorescein
isothiocyan
fitc
label
monoclon
antibodi
use
confirm
presenc
influenza
viru
rsv
cell
isol
nasal
wash
dri
microscop
slide
fix
aceton
subsequ
cell
stain
fitc
conjug
monoclon
antibodi
influenza
viru
influenza
b
viru
rsv
imagen
tm
influenza
b
imagen
tm
rsv
hampshir
unit
kingdom
specimen
incub
fitcconjug
antibodi
min
c
subsequ
excess
reagent
wash
phosphat
buffer
salin
stain
area
mount
view
fluoresc
microscopi
focu
studi
compar
data
obtain
two
radt
bni
bnr
obtain
rtpcr
gold
standard
defin
falseneg
test
rapid
test
neg
gold
standard
rtpcr
posit
falseposit
test
result
defin
rapid
test
test
posit
gold
standard
rtpcr
test
neg
compar
avail
ctvalu
respect
categori
sampl
analys
whether
associ
ctvalu
radt
result
hospit
influenza
ctvalu
avail
rsv
ctvalu
avail
perform
test
miss
ctvalu
sampl
test
routin
input
ctvalu
laboratori
system
yet
perform
digit
document
avail
final
falseneg
falseposit
test
result
compar
test
result
obtain
viru
detect
method
viru
isol
dif
assay
main
outcom
studi
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
bni
bnr
rapid
test
result
compar
rtpcr
total
studi
period
viral
season
octob
march
ctvalu
compar
mannwhitney
u
test
also
calcul
paramet
sampl
obtain
period
octob
march
respiratori
virus
preval
netherland
sensit
specif
decreas
respect
ppv
npv
decreas
respect
nasal
wash
rsv
rtpcr
bnr
data
avail
case
rsv
rtpcr
posit
ctvalu
avail
sampl
rang
median
ctvalu
bnr
posit
tabl
hundr
sixtytwo
sampl
rtpcr
posit
bnr
posit
median
ctvalu
ctvalu
avail
n
fortytwo
case
consid
falseneg
median
ctvalu
ctvalu
avail
n
rtpcr
neg
case
five
bnr
posit
consid
falseposit
case
also
calcul
paramet
respiratori
viru
season
octobermarch
sensit
increas
specif
remain
ppv
increas
npv
decreas
respect
eleven
falseneg
bni
case
influenza
viru
success
isol
six
case
median
ctvalu
three
also
influenza
dif
posit
mean
rtpcr
viru
isol
dif
sampl
test
posit
anoth
viru
frequent
rsv
n
adenoviru
adv
n
see
supplement
tabl
onlin
version
doi
bnr
result
consid
falseneg
case
rsv
cultur
success
case
ctvalu
rang
median
addit
case
rsv
dif
test
posit
median
ctvalu
coinfect
found
case
often
hrv
n
four
case
bni
test
posit
influenza
could
confirm
three
sampl
rtpcr
see
supplement
influenza
falseposit
case
six
test
posit
bnr
moreov
six
case
test
rsv
rtpcr
posit
five
also
bnr
posit
eight
sampl
anoth
respiratori
viru
influenza
viru
rsv
detect
rtpcr
two
sampl
dif
posit
influenza
accord
bni
viru
isol
yield
influenza
viru
see
supplement
bnr
five
falseposit
case
found
three
rsv
posit
viru
isol
dif
one
case
test
neg
method
except
bni
see
supplement
tabl
onlin
version
doi
sensit
specif
ppv
increas
consid
three
rsv
posit
viru
isol
trueposit
case
result
two
falseposit
case
patient
test
bni
bnr
patient
hospit
hospit
rate
trueposit
bni
bnr
case
respect
falseneg
test
result
seem
major
impact
hospit
hospit
rate
vs
p
vs
p
bni
bnr
test
result
respect
tabl
compar
ctvalu
respect
categori
bni
bnr
case
falseneg
display
overal
higher
ctvalu
p
vs
p
fig
b
howev
differ
found
ctvalu
hospit
nonhospit
patient
within
respect
case
group
p
bni
bnr
fig
b
bni
test
result
differenti
sever
diseas
three
falseneg
case
admit
paediatr
intens
care
unit
picu
also
three
present
studi
evalu
diagnost
perform
bni
bnr
radt
larg
number
symptomat
paediatr
patient
year
attend
tertiari
care
paediatr
hospit
almost
eight
consecut
year
test
fresh
nasal
wash
rtpcr
found
rel
low
sensit
ppv
bni
overal
test
perform
bnr
score
higher
aspect
bni
bnr
falseneg
case
display
significantli
higher
ctvalu
compar
rtpcr
posit
trueposit
test
case
accuraci
rapid
test
gener
less
rtpcr
viru
isol
assay
howev
radt
valuabl
pointofcar
test
eas
use
fast
result
laboratori
independ
advantag
especi
high
specif
import
use
surveil
tool
influenza
outbreak
recommend
world
health
organ
inde
surveil
purpos
high
specif
import
found
case
studi
howev
clinic
manag
suffici
theori
decis
start
antivir
therapi
refrain
unnecessari
diagnost
test
antibiot
use
may
base
radt
addit
rapid
test
result
may
result
effect
isol
contain
measur
purpos
assay
sensit
utmost
import
therefor
conclud
rel
low
sensit
bni
tertiari
care
centr
worrisom
note
bnr
test
perform
prove
better
compar
bni
although
falseneg
case
detect
base
result
stop
use
bni
use
rapid
pcrbase
test
detect
influenza
viru
rsv
consid
clinic
implic
falseneg
falseposit
test
result
relat
hospit
found
signific
differ
group
rtpcr
posit
bni
posit
test
case
indic
clinic
observ
still
pivot
admiss
decisionmak
suggest
current
guidelin
present
studi
abl
studi
effect
test
treatment
sinc
antivir
medic
routin
use
hospit
data
isol
contain
measur
avail
although
retrospect
natur
studi
inher
limit
abl
includ
sampl
patient
time
sinc
studi
span
consider
longer
period
time
previou
studi
abl
test
clinic
feasibl
radt
real
life
clinic
set
differ
circul
viru
subtyp
eight
consecut
season
overal
studi
report
high
specif
high
npv
versu
low
sensit
low
ppv
bni
larg
agreement
result
find
rel
high
sensit
even
higher
ppv
bnr
agreement
data
obtain
studi
last
decad
rtpcr
becom
gold
standard
detect
presenc
respiratori
virus
downsid
rtpcr
rel
long
time
h
sampl
collect
avail
test
result
make
current
rtpcr
format
less
use
admiss
decisionmak
call
faster
method
inde
new
rapid
pointofcar
pcr
develop
implement
shorter
turnaround
time
studi
compar
perform
rtpcr
would
allow
us
judg
potenti
clinic
decisionmak
conclus
evalu
perform
radt
bni
bnr
tertiari
care
paediatr
hospit
set
eight
consecut
year
show
sensit
ppv
bni
rel
low
wherea
bnr
higher
compar
respect
gold
standard
rtpcr
falseneg
sampl
consist
display
high
ctvalu
although
influenc
whether
patient
hospit
given
rel
low
sensit
ppv
bni
strongli
advoc
restrict
use
bni
similar
rapid
influenza
antigen
detect
assay
tertiari
paediatr
care
set
contrast
higher
sensit
ppv
bnr
render
rapid
test
use
albeit
still
less
sensit
rtpcr
pf
particip
iri
trial
sponsor
hoffmannla
roch
pf
mk
ao
receiv
fund
eu
project
prepar
studi
pathogenesi
virus
children
pf
ao
receiv
fund
virgo
project
nwo
netherland
ao
receiv
fund
nrennt
dfg
germani
data
collect
analys
conduct
anonym
sampl
requir
medic
ethic
review
consent
medic
ethic
board
